Fotagliptin

Fotagliptin
Clinical data
Other names	SAL067
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 2-[[3-[(3R)-3-Aminopiperidin-1-yl]-6-methyl-5-oxo-1,2,4-triazin-4-yl]methyl]-4-fluorobenzonitrile;
CAS Number	1312954-58-7;
PubChem CID	53258570;
ChemSpider	88297640;
ChEMBL	ChEMBL5408495;
Chemical and physical data
Formula	C17H19FN6O
Molar mass	342.378 g·mol−1

Fotagliptin (SAL067) is a DPP-4 inhibitor under development for the treatment of type 2 diabetes. Like other DPP-4 inhibitors, it works by increasing endogenously produced GLP-1 and GIP.^[1]^[2]^[3] In a phase 3 trial it showed similar results as alogliptin.^[4]

Other namesSAL067

Legal status

Investigational

CAS Number

1312954-58-7

PubChem CID

53258570

Quick facts Clinical data, Other names ...

Close

[1]

[2]

[3]

[4]

Fotagliptin

References

Related Articles

Related Articles

"Safety, Pharmacokinetics, and Pharmacodynamics of a Dipeptidyl Peptidase-4 Inhibitor: A Randomized, Double-Blinded, Placebo-Controlled Daily Administration of Fotagliptin Benzoate for 14 Days for Type 2 Diabetes Mellitus"

"Ultrasound-assisted solution crystallization of fotagliptin benzoate: Process intensification and crystal product optimization"

"Fotagliptin monotherapy with alogliptin as an active comparator in patients with uncontrolled type 2 diabetes mellitus: a randomized, multicenter, double-blind, placebo-controlled, phase 3 trial"